Merck (MRK) P/E (2009 - 2026)
Merck (MRK) P/E from Jun 30, 2009 to Jul 20, 2026. The TTM Merck (MRK) P/E is 27.10. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Merck (MRK)
| Year | P/E | Change |
|---|---|---|
| 2026 | 27.10 | +98.08% |
| 2025 | 13.68 | +3.04% |
| 2024 | 13.28 | -75.61% |
| 2023 | 54.44 | +226.57% |
| 2022 | 16.67 | +7.67% |
| 2021 | 15.48 | -13.42% |
| 2020 | 17.88 | -24.98% |
| 2019 | 23.84 | -46.99% |
| 2018 | 44.97 | +71.37% |
| 2017 | 26.24 | +6.49% |
| 2016 | 24.64 | -24.76% |
| 2015 | 32.75 | +18.63% |
| 2014 | 27.61 | +3.08% |
| 2013 | 26.78 | +56.28% |
| 2012 | 17.14 | -21.10% |
| 2011 | 21.72 | +21.74% |
| 2010 | 17.84 | +10.02% |
| 2009 | 16.22 | N/A |
Comparison Merck (MRK) P/E with competitors
Merck (MRK) P/E is 27.10.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -62.69% |
| PFE | Pfizer Inc | 11.65 | -56.99% |
| NVO | Novo Nordisk | 11.79 | -56.49% |
| GSK | GSK Plc | 12.10 | -55.33% |
| SNY | Sanofi | 12.12 | -55.26% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -49.00% |
| OGN | Organon & Company | 14.33 | -47.13% |
| BIIB | Biogen Inc | 17.41 | -35.77% |
| GILD | Gilead Sciences Inc | 17.75 | -34.52% |
| NVS | Novartis AG | 21.60 | -20.30% |
| JNJ | Johnson & Johnson | 22.09 | -18.49% |
| AMGN | AMGEN Inc | 24.75 | -8.66% |
| AZN | Astrazeneca plc | 28.44 | +4.96% |
| LLY | Lilly(Eli) & Company | 48.44 | +78.76% |
| ABBV | Abbvie Inc | 139.08 | +413.23% |